ENDO INTERNATIONAL PLC news, videos and press releases - Page 2
For more news please use our advanced search feature.
ENDO INTERNATIONAL PLC - More news...
ENDO INTERNATIONAL PLC - More news...
- Endo Presents New Data at the American Podiatric Medical Association Annual Meeting
- Endo Launches First Generic Version of Noxafil® (posaconazole) Injection
- Endo Announces Approval of XCOPRI™ (cenobamate tablets) in Canada
- Endo Announces First Patient Enrolled in Registry of Dupuytren's Contracture
- Late-Breaking Results of a Preclinical Efficacy Study Presented at ENDO 2023 Show Seraxis SRE Sustainably Reverses Type-1-Diabetes Hyperglycemia
- Endo Launches Dexlansoprazole Capsules, Generic Version of Dexilant®
- Spruce Biosciences Announces Acceptance of Abstract for Presentation at the Annual Meeting of the Endocrine Society (ENDO 2023)
- Endo Launches PREVDUO™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Pre-Filled Syringe
- Horizon Therapeutics plc Announces Data from the TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease (TED) to be Presented at the Upcoming Endocrine Society (ENDO) Annual Meeting
- Endo Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Data Analysis in Peer-Reviewed Urology®
- Endo Announces Agreement with MAIA Pharmaceuticals to Distribute Bivalirudin Injection in Ready-to-Use Vials
- ENDO REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTS
- ENDO REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTS
- Endo Announces Agreement with Slayback Pharma to Distribute Prevduo™ (neostigmine methylsulfate and glycopyrrolate injection), the First and Only FDA-Approved Neostigmine-Glycopyrrolate Combination Product in the U.S.
- IF YOU, A CHILD IN YOUR CARE, OR ANOTHER LOVED ONE WERE HARMED BY ENDO OR A RELATED COMPANY, INCLUDING PAR OR AMS, OR THEIR PRODUCTS INCLUDING OPIOIDS, RANITIDINE, OR TRANSVAGINAL MESH, YOUR RIGHTS MAY BE AFFECTED BY DEADLINES IN THE ENDO BANKRUPTCY.
- Endo Announces Launch of Argatroban Injection Through Premier's ProRx® Private-Label Program
- Endo Launches Authorized Generic Version of Noxafil® (posaconazole) Oral Suspension
- Endo Provides Top-Line Results from Phase 2 Study of Collagenase Clostridium Histolyticum (CCH) in Participants With Plantar Fibromatosis
- Endo Launches First Generic Version of Pylera® (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) Capsules
- ENDO REPORTS FOURTH-QUARTER 2022 FINANCIAL RESULTS
- ENDO REPORTS FOURTH-QUARTER 2022 FINANCIAL RESULTS
- Endo Launches "Man With a Plan" Campaign to Support Men With Symptoms of Peyronie's Disease
- Endo to Cease Production and Sale of Qwo® (collagenase clostridium histolyticum-aaes)
- ENDO REPORTS THIRD-QUARTER 2022 FINANCIAL RESULTS
- ENDO REPORTS THIRD-QUARTER 2022 FINANCIAL RESULTS
- Endo and SMSNA Launch App to Provide Peyronie's Disease Self-Assessment Tool
- Endo Presents New Qwo® (collagenase clostridium histolyticum-aaes) Data at the American Society for Dermatologic Surgery's Annual Meeting
- Endo Launches Unscripted Video Series With Real Dupuytren's Contracture Patients
- Thinking about buying stock in Mind Medicine, Endo International, Tilray, BioNano Genomics, or Nikola Corp?
- Endo Enters Into Restructuring Support Agreement with Senior Secured Debtholders to Strengthen Financial Position and Advance Ongoing Business Transformation